VIR · XBRL financial data

Vir Biotechnology financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VIR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	76	1,095	1,616	86	74	69
Revenue from contracts with customers	—	—	1,616	86	74	69
Cost of revenue	0	66	146	3	1	0
Research and development	302	448	475	590	506	456
Selling, general and administrative	71	161	162	178	119	92
General and administrative	71	—	—	—	—	—
Total operating expenses	373	—	—	—	—	—
Operating income (loss)	(297)	421	833	(684)	(587)	(479)
Interest income	—	—	28	87	72	40
Other income (expense)	(4)	(9)	4	(9)	(2)	(0)
Income tax expense (benefit)	0	21	238	(13)	(1)	0
Net income (loss)	(299)	529	516	(615)	(522)	(438)
Earnings per share, basic USD per share	(2.51)	4.07	3.89	(4.59)	(3.83)	(3.16)
Earnings per share, diluted USD per share	(2.51)	3.96	3.83	(4.59)	(3.83)	(3.16)
Weighted average shares, basic millions of shares	119	130	133	134	136	139
Weighted average shares, diluted millions of shares	119	133	135	134	136	139

Fiscal years (VIR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	437	348	849	242	223	232
Marketable securities	300	217	1,522	1,271	678	229
Accounts receivable	0	773	0	—	—	—
Prepaid and other current assets	28	73	104	53	48	45
Total current assets	772	1,563	2,519	1,588	1,042	514
Property and equipment, net	18	43	106	96	63	56
Right-of-use asset	62	87	83	71	60	62
Goodwill	17	17	17	17	17	17
Total assets	919	1,954	2,802	1,919	1,399	1,003
Accounts payable	5	7	6	6	5	10
Total current liabilities	99	341	511	175	120	93
Lease liability, non-current	67	134	124	112	90	89
Total liabilities	202	522	724	329	248	238
Retained earnings (accumulated deficit)	(667)	(139)	377	(238)	(760)	(1,198)
Total stockholders' equity	717	1,432	2,078	1,590	1,150	765
Total liabilities and equity	919	1,954	2,802	1,919	1,399	1,003
Common shares outstanding (cover page) millions of shares	128	132	134	135	137	140

Fiscal years (VIR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(299)	529	516	(615)	(522)	(438)
Stock-based compensation	28	84	102	111	78	49
Depreciation and amortization	4	5	6	19	15	12
Net cash from operating activities	(191)	(48)	1,663	(779)	(446)	(392)
Purchases of property and equipment	7	22	68	22	7	5
Net cash from investing activities	(10)	(141)	(1,193)	165	499	310
Proceeds from issuing common stock	323	0	0	—	—	—
Net cash from financing activities	529	100	35	7	4	4
Net change in cash	329	(88)	505	(607)	57	(78)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Vir Biotechnology	219	(0.2)	(106)*	171.3M	11.8 quarters	Q3 FY26 10-QSep 30, 2026
ImmunityBio	76	51	(66)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Anaptysbio	134	27*	(27)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	205	208	43*	42.7M	—	Q3 FY26 10-QSep 30, 2026
Pacira BioSciences	247	177	50*	40.1M	—	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 12:50 PM ET. The filing on SEC.gov is the record.